Conference on 4th Annual Recombinant Antibodies
Venue: BSG Conference Centre
|Event Date/Time: Jan 19, 2011||End Date/Time: Jan 21, 2011|
4th Annual Recombinant Antibodies( Conference and Workshop)
19th â€“ 21st January 2011, BSG Conference Centre, London, UK
Improving design, engineering and immunoclinical outcomes
Sylke Poehling, Senior Director Biologics Discovery, Pharma Research and Early Development, Roche
Frank Brennan, Principal Safety Assessment Expert, Novartis
Rolf Werner, Corporate Senior Vice President, Biopharmaceuticals, Boehringer Ingelheim
Leopold Bertea, Vice President, Biologics Center, Sanofi -Aventis, R&D
Christian Blot, Associate Director, Global Regulatory Affairs - Drug Safety & Animal Research Interface, Sanofi -Aventis
Ulrich Haupts, Director, Protein Optimisation, Bayer Schering Pharma
Jill Carton, Associate Director, Biologics Research, Centocor
Matthew Sleeman, Director of Biology, MedImmune
Lolke De Haan, Head of Toxicology, MedImmune
Andrew Nesbitt, Director of the Cimzia Mode of Action Group, UCB Celltech
Alain Pralong, Vice President, Process Development, Crucell
Kerry Chester, Professor of Molecular Medicine, University College London
As shown by Rituxan and Herceptin, antibodies have blockbuster potential and now number eight of todayâ€™s 20 top-selling biotech drugs1. With ongoing growth rates pushing 15%, the global market will reach $70bn by 2013 as new approvals and a growing world population drive patient demand2,3.
With over 25 products approved for human use and 26 candidates in Phase III trials1,2,mAbs remain arguably the most exciting proteins today. Pharmaceutical companies have become more interested, especially in antibody fragments, as these progress through development for new indications including respiratory, cardiovascular and viral diseases1,3.
With competition intensifying, improving engineering, development and production has become ever more important in todayâ€™s economic climate. This includes testing in vivo efficacy and effectiveness for humanised / fully human therapies and enhancing the half-life of small proteins4. Decreasing immunogenicity, improving cell line productivity and decreasing manufacturing costs remain ongoing challenges, as do more effective biodistribution, targeting, tissue penetration and uptake 4, 5.
Addressing these issues, Fourth Annual Recombinant Antibodies conference showcases how such goals are being met by leading experts. Whether your interests lie in basic, pre-clinical, translational or clinical research, business diversification, licensing or partnering, attending this meeting will empower you to:
â€¢ Improve product valency, affinity and avidity for receptors or ligands
â€¢ Counteract proteolytic degradation, renal removal and immunocomplex formation
â€¢ Better utilise, deploy and evaluate in silico tools during early-phase research
â€¢ Overcome protein aggregation in clinical development
â€¢ Enhance physicochemical and pharmacokinetic properties to prolong or decrease circulating antibody half-life and exposure
â€¢ Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity
â€¢ Optimise the potency of IgG molecules for ADCC, ADCP or CDC applications
â€¢ Examine prospects for second and third generation therapeutics including Fab, scFv, bispecific, and alternative scaffold technologies
â€¢ Maximise site-specific drug loading for chemical conjugates
â€¢ Obtain new data on applications for infl ammatory diseases, and solid and haematological tumours
â€¢ Employ improved HTS tools and choose the right species for in vivo trials
â€¢ Decrease production and processing costs and boost antibody expression, yield, delivery and safety
Who should attend this conference?
Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Professors, Heads, Directors, Principal/Senior Scientists and Managers/Team Leaders of:
â€¢ Antibody design, production and development
â€¢ Recombinant DNA/molecular biotechnology
â€¢ Protein/biochemical engineering
â€¢ Assay and cell display technologies
â€¢ Bio-analytical and protein-analytical R&D, and analytical chemistry
â€¢ Process development â€¢ Preclinical/clinical research and development
â€¢ CNS, autoimmune and inflammatory disease research
â€¢ Arthritis, colorectal/breast/lymphoma/prostate/lung cancer R&D
â€¢ Immunobiology and immunogenicity testing
â€¢ Business and alliance development
â€¢ Marketing and licensing
â€¢ Contract manufacturing and research organisations
â€¢ Regulatory affairs, pharmaceutical and patent law
â€¢ Pharmaceutical and patent law
Pre-Conference Interactive Workshop
Wednesday 19th January 2011
From stainless steel to disposable technology - a leap in the manufacturing of biopharmaceuticals
What will be learnt:
Traditional chemical engineering technology based on stainless steel has been applied as standard in the manufacturing of biopharmaceuticals over the past 30 years. Increasing requirements for quality and process control, combined with relatively low product titers, have resulted in highly complex and expensive equipment and facility layouts. The construction and commissioning of a new facility can take five to seven years and cost more than â‚¬350 million.
Over the past 15 years, significant efforts have been made to increase process productivity and develop new manufacturing technologies that permit a reduction in CAPEX and OPEX costs. Major developments in disposable technology since 2000 have resulted in the possibility of replacing traditional stainless steel equipment. This combination of process productivity and new technologies has had a significant impact on strategies for developing and manufacturing biopharmaceuticals, and reducing associated costs.
In this workshop, we review the development of disposable technology, its implementation and opportunities that remain unfulfilled. This is presented with Crucellâ€™s view on the future manufacturing of biopharmaceuticals.